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Background/Aims. Diabetic patients usually require more medications than their nondiabetic counterparts. This work examined
the eﬀect of hyperglycemia on the pharmacokinetic properties of cyclosporine in a diabetic dog model. Main Methods. Diabetes
was induced using a streptozotocin/alloxan combination and veriﬁed by measuring the serum glucose level. Cyclosporine was
administered as a bolus intravenous dose of 5mg/kg, and blood samples were collected at diﬀerent time points for determining
drug concentrations and biochemical analyses. Results. Diabetic dogs showed a signiﬁcant increase in total body clearance of
cyclosporine compared to healthy controls (0.457L hr
−1Kg
−1 versus 0.201L hr
−1Kg
−1, P = .0019) and a decrease in its biological
half-life (9.32hours versus 22.56hours, P = .0125). In addition, diabetic animals exhibited a higher total cholesterol (7.20 ±
0.62mmol/L and 5.28 ± 0.36mmol/L; P<. 05) as well as more serum low density lipoproteins (4.45 ± 0.72mmol/L versus 1.06 ±
0.10mmol/L;P<. 05).Conclusion.Overtdiabetesalterscyclosporinedispositionbymodulatingitsclearance.Abnormalitiesinthe
lipid proﬁle, among other factors, may contribute to the accelerated metabolic degradation of cyclosporine under hyperglycemic
conditions.
Copyright © 2009 Khalid M. Alkharfy. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Diabetes mellitus is a complex metabolic disorder that
aﬀects a signiﬁcant fraction of the global population and its
management without any side eﬀects is still a major health
problem [1–3]. Because of the increased morbidity and
mortality of diabetes, more drugs are prescribed to diabetic
patients than age-matched nondiabetic people [4, 5]. In
many instances, drug therapy in diabetes may involve highly
potent drugs or agents with narrow therapeutic ranges.
Furthermore, a signiﬁcant proportion of diabetic patients
develop end stage renal failure, and thus, kidney transplan-
tation is not uncommon among them [6, 7]. Diabetes may
also ensue following organ transplantation in about 20% of
organ recipients because of the immunosuppressive therapy,
a condition that is commonly known as post-transplant
diabetes [8, 9].
It has been proposed that diabetes mellitus may alter
the pharmacokinetics of some drugs [10–12]. In essence,
diabetes may inﬂuence the pharmacokinetic characteristics
of drugs by aﬀecting drug absorption–due to gastroparesis
or delayed gastric emptying, protein binding–because of
glycation of albumin and metabolism owing to diﬀerential
regulation of drug-metabolizing enzymes [10, 11, 13]. For
example,theincreasedplasmaconcentrationsoftriglycerides
and free fatty acids due to diabetes can alter the plasma
protein binding of drugs [13]. Some investigations have also
demonstrated that uncontrolled diabetes in experimental
animal models result in enhanced expression of several
cytochromeP450(CYP)isoforms(CYP2E1,CYP2B,CYP3A,
and CYP4A) which can be normalized by insulin therapy
[13–16].Fujiietal.reportedthatchemicallyinduceddiabetic
mice showed hyposensitivity to pentobarbital manifested
by shortening of sleeping time as a result of abnormal
hepaticdrugmetabolism[17].Themetabolismofantipyrine
is also increased in patients with type 1 diabetes melli-
tus, which appears to be due to an increase in CYP1A2
activity [18]. However, changes in drug pharmacokinetics2 Experimental Diabetes Research
and pharmacodynamics due to diabetes have not yet fully
been characterized. Therefore, to improve eﬃcacy and
safety of drug therapy in diabetic patients, the eﬀects of
hyperglycemia and associated metabolic abnormalities on
drug disposition and pharmacological eﬀects require further
exploration.
Cyclosporine A, a lipophilic cyclic polypeptide with
immunomodulating properties, has successfully been used
for preventing organ transplant rejection [19, 20]. Despite
many years of experience, protocols that optimize immuno-
suppressive drugs eﬃcacy with minimal toxicity remain a
subject of debate. Studies of the pharmacokinetic proper-
ties of the calcineurin inhibitors, particularly cyclosporine,
have led to improved dosing strategies. The therapeutic
outcome depends on cyclosporine exposure, which might
be characterized by the area under the drug concentration-
time curve [21, 22]. Among various factors that inﬂuence
cyclosporinevariabilitybetweenpatientsistheconcentration
of lipoproteins which can modulate cyclosporine binding
in plasma (free fraction ∼1-2%). Other factors include
age, the time posttransplantation, drug interactions, and
presystemic elimination by CYP3A or the eﬄux transporter
P-glycoprotein in the gastrointestinal tract [23–25].
Due to the adverse eﬀects of cyclosporine on glucose
metabolism as well as its potential use in diabetics following
kidney/pancreas transplantation, it is of interest to examine
the inﬂuence of hyperglycemic state on cyclosporine disposi-
tion; this is important because little information is available
in literature for this eﬀect. Therefore, a series of experiments
were conducted to study cyclosporine pharmacokinetics in
diabetic dogs and to evaluate diabetes-related factors inﬂu-
encing the variability of cyclosporine blood concentrations.
2.MaterialandMethods
2.1. Experimental Animals. Age-matched healthy adult Bea-
gle dogs weighing 8.4–12.8kg, obtained from the College
of Pharmacy Animals Care and Use Facility at king Saud
University (Riyadh, Saudi Arabia), were used in the study.
Animal were maintained in accordance with the recommen-
dations of the “Guide for the Care and Use of Laboratory
Animals” approved by the Facility. They were housed in
a temperature-controlled room with a 12-hour light/dark
cycle for at least 1 week before the experiments and allowed
free water and food ad libitum during the study with the
exception that the chow was pulled twelve hours prior to
animals’ dosing.
Dogs were randomly divided into two groups (N = 5
dogs each). Control group was assigned to receive cyclos-
porine (Novartis, Basel, Switzerland) 5mg/kg via a slow
intravenous (IV) bolus administration. The other group
was subjected to diabetes induction using an IV bolus
dose of streptozotocin 50mg/kg and alloxan 50mg/kg (both
obtainedfromSigma-Aldrich,St.Louis,MO,USA).Diabetic
status was conﬁrmed by measuring fasting serum sugar
(FSG)threeandtendaysfollowingdiabetesinduction.Those
dogs showing FSG of 10mmol/L or greater were included in
the experiments.
Treatment with cyclosporine was started ten days after
diabetic induction in the beagle dog model with a slow
intravenous (IV) bolus of 5mg/kg through a major leg vein.
Blood samples of 1mL were collected from counterpart
leg veins through an indwelling vein catheter into EDTA
vacutainers. Blood samples were collected at diﬀerent time
points: 0, 0.083, 0.25, 0.5, 1.25, 1.5, 3, 6, 8, 10, 12, and 24
hours following cyclosporine administration. In all experi-
ments, equal volumes of normal saline were injected through
the cannula to replace the ﬂuid loss. Pharmacokinetic and
biochemical analyses were carried out on collected samples
from diabetic and control dogs.
2.2. Cyclosporine and Biochemical Analysis. Measurements
of cyclosporine blood levels were carried out using mono-
clonal whole blood ﬂuorescence polarization immunoassay
(TDx system, Abbott Technologies, Abbott Park, IL, USA).
Biochemical analysis of some relevant parameters such as
kidney function tests (i.e., serum creatinine and blood urea
nitrogen) and lipid proﬁle including total cholesterol, high-
density lipoproteins (HDL), low-density lipoproteins (LDL),
a n dt r i g l y c e r i d ew e r em e a s u r e di nt h ep l a s m ao fe a c hd o gb y
drawing blood sample just before commencing cyclosporine
administration. All biochemical parameters were analyzed
by BioSystems kits (BioSystems SA, Barcelona, Spain). The
intra- and interday variability of the cyclosporine assay and
biochemical analysis were <15%.
2.3. Pharmacokinetic Analysis. Pharmacokinetic parame-
ters of cyclosporine were determined by using two-
compartmental pharmacokinetic model performed with
WinNonlin software (Version 4.1, Pharsight Corporation,
Palo Alto, CA, USA). Inspection of semilogarithmic plots
of cyclosporine blood concentration-time curves indicated
that they could be described by a biexponential decay
process. Therefore, the data were initially ﬁtted to one, two,
and three compartment models for the best ﬁt. The best
ﬁt was based on Akaike criterion and Schwarz’s criterion,
analysis of residual plots, and correlation matrixes. All blood
concentration data were weighted according to 1/y2,w h e r e
y is the plasma concentration of cyclosporine. The esti-
mated pharmacokinetic parameters included the intercepts
A and B and the macrorate constants α and β. Additional
computed parameters are volume of distribution of the
central compartment (V1), volume of distribution of the
peripheral compartment (V2), and the microrate constants
(K12,K 21 and K10). The noncompartmental analysis was
used to estimate the volume of distribution at steady state as
(AUMC0−∞/AUC0−∞)
∗CL and total body clearance (CL) as
dose/AUC0−∞,w h e r eA U M C 0−∞ is the area under moment
curve and AUC0−∞ is the area under the concentration
versus time curve from time zero to inﬁnity. AUC0−∞ was
calculated using the trapezoidal rule as the sum of AUC0−t
and any residual area (i.e., extrapolation to inﬁnity) which
was computed as the concentration at the last time point by
the terminal rate constant. The cyclosporine apparent elim-
ination rate constant (λz) was estimated by linear regressionExperimental Diabetes Research 3
analysis of the terminal portion of the log concentration-
timedata.Cyclosporineapparenteliminationhalf-life(T1/2λ)
was computed as ln2/λ.
2.4. Statistical Analysis. Data are presented as the
mean±SEM. Diﬀerences in pharmacokinetic parameters of
cyclosporine as well as in the biochemical measurements
between healthy control and diabetic dogs were assessed
by an unpaired t-test on log-transformed data. Statistical
signiﬁcance will be assumed when P ≤ .05. All calculations
were performed using GraphPad Prism version 3.00 for
Windows (San Diego, CA, USA).
3. Results
Treatment with streptozotocin/alloxan combination induced
diabetes in treated animals within 10 days of administration
as veriﬁed by measuring serum glucose concentration which
d e m o n s t r a t e dam e a no f2 4 .70 ± 4.63 mmol/L in diabetic
dogs versus 6.88 ±0.69 mmol/L in healthy dogs (P = .0003).
This hyperglycemicstate wasalso associated with adisturbed
serum lipid proﬁle (i.e., dyslipidemia), which manifested as
an increase in total cholesterol and LDL levels of 7.20 ±
0.65mmol/L and 4.45 ± 0.72mmol/L in diabetic dogs as
compared to 5.28 ± 0.36mmol/L and 1.06 ± 0.10mmol/L
in healthy dogs, respectively (P<. 05). Other biochemical
measures including serum creatinine, blood urea nitrogen,
triglyceride,andHDLdidnotdiﬀersigniﬁcantlybetweenthe
two groups (Table 1).
Two-compartment pharmacokinetic analysis of whole
blood cyclosporine concentration-time proﬁle of diabetic
dogs revealed a signiﬁcant increase in α rate constant of
120% and β rate constants of 262% when compared with
normoglycemic dogs (Table 2). Also, the rate constant of
drugtransferfromtheperipheralcompartmenttothecentral
compartment (K21) was 336% higher in diabetic dogs than
healthy dogs value (P = .0186). Noncompartmental phar-
macokinetic analysis of cyclosporine concentrations during
hyperglycemia also revealed a signiﬁcant reduction in mean
resident time (MRT) and area under concentration-time
curve (AUC0−∞) amounting to 59% and 52%, respectively
(Figure 1, Table 3). Moreover, diabetic dogs demonstrated a
signiﬁcant increase in cyclosporine clearance with a decrease
in its biological half-life (0.457L hours−1 kg−1 and 9.32
hours) compared to healthy dogs (0.201L hours−1 kg−1 and
22.56 hours) (P<. 05). Cyclosporine’s steady-state volume
of distribution (Vss) was not modiﬁed by diabetes in the
treated dogs (P = .2468).
4. Discussion
Thepresentworkhasdemonstratedthatdiabeticdogsexhib-
itedanalteredpharmacokineticproﬁleofanIVadministered
cyclosporine as compared to normoglycemic animals. Dia-
beticdogsshowedsigniﬁcantincreaseinthedistributionand
elimination of cyclosporine as measured by its disposition
half-lives (T1/2α and T1/2β). In addition, an increase in the
rate constant of cyclosporine transfer from the peripheral
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Figure 1: Blood concentration versus time curve of cyclosporine
following an intravenous administration of 5mg/kg dose to healthy
and diabetic beagle dogs (N = 5 each).
compartment to the central compartment (i.e., K21)h a s
also been observed indicating a signiﬁcant redistribution of
cyclosporine out of tissues. This can increase the availability
ofcyclosporineforeliminatingorgans(e.g.,liverandkidney)
to remove drug faster and therefore shorten its elimination
half-life as seen in this study.
The mechanism of the phenomenon is not entirely
understood; however, it could be related to the state
of hyperlipoproteinemia that is associated with glucose
intolerance. Saad and Najjar reported that streptozotocin-
induced diabetes contributestoa disturbed lipid proﬁle[26].
Diabetic dogs in the current study developed a statistically
signiﬁcant higher level of total cholesterol and LDL. In
plasma, cyclosporine is predominantly bound to very low-
density lipoprotein (VLDL) (10%), LDL (35%) and HDL
(33%), and a small remaining portion (10–15%) binds to
albuminandglobulin[27,28].Therefore,hyperglycemiaand
associated dyslipidemia may play a crucial role in the phar-
macokinetic behavior of cyclosporine during diabetes. Inter-
estingly, Aliabadi and colleagues have also demonstrated that
hyperlipoproteinemia aﬀects biodistribution of cyclosporine
in a rat model. Compared with normolipidemic animals,
hyperlipoproteinemic rats had higher plasma, blood, kidney,
and liver cyclosporine concentrations [29]. Furthermore,
hypercholesterolemia may also attenuate cellular and clinical
cyclosporine pharmacodynamics and modulate its uptake by
hepatocytes [30, 31].
Cyclosporine is a highly protein-bound drug with a
low to intermediate hepatic extraction ratio, and thus, its
clearance is dependent on the free fraction and intrinsic
clearance and possibly blood ﬂow to eliminating organs.
Integrity of hepatic metabolic function signiﬁcantly inﬂu-
ences the cyclosporine pharmacokinetics and diabetogenic
agents modify diﬀerentially and selectively CYP isoenzymes
[32]. In fact, diabetes induction by streptozotocin does
not change the amount of microsomal protein within the4 Experimental Diabetes Research
Table 1: Biochemical parameters in healthy and diabetic beagle dogs.
Parameter Group Mean ± SEM P value
Fasting serum glucose (mmo/L) Healthy 6.88 ±0.69 .0003
Diabetic 24.7 ±4.63
Total cholesterol (mmo/L) Healthy 5.28 ±0.36 .0279
Diabetic 7.2 ±0.65
High-density lipoprotein (mmo/L) Healthy 3.38 ±0.25 .8331
Diabetic 3.31 ±0.28
Low-density lipoprotein (mmo/L) Healthy 1.06 ±0.1 .0001
Diabetic 4.45 ±0.72
Triglyceride (mmo/L) Healthy 0.73 ±0.14 .5042
Diabetic 0.96 ±0.23
Serum creatinine (μmo/L) Healthy 65.6 ±1.69 .0885
Diabetic 54.8 ±5.92
Blood urea nitrogen (mmo/L) Healthy 4.0 ±0.85 .6719
Diabetic 4.3 ±0.66
Table 2: Compartmental pharmacokinetic parameters of cyclosporine following an intravenous administration of 5mg/kg in healthy and
diabetic beagle dogs.
Parameter Estimate (Mean ± SEM)
Healthy dog Diabetic dog P value
A( μgL −1) 3676.57 ± 857.15 2866.58 ± 419.88 .4237
B( μgL −1) 553.77 ± 92.76 738.09 ± 79.93 .1706
α (hr−1)0 . 7 4 ± 0.28 1.63 ± 0.36 .0477
β (hr−1) 0.026 ± 0.008 0.094 ± 0.026 .0207
K12(hr−1)0 . 5 3 ± 0.25 0.89 ± 0.22 .1404
K21(hr−1)0 . 1 1 ± 0.022 0.48 ± 0.16 .0186
K10(hr−1)0 . 1 3 ± 0.03 0.34 ± 0.07 .1076
V1 (L kg−1)1 . 3 5 ± 0.16 1.49 ± 0.22 .5669
V2 (L kg−1)6 . 9 5 ± 2.86 3.04 ± 0.38 .1788
liver, but the hepatic CYP content and enzyme activity are
signiﬁcantlyincreased [33]. Furthermore, due to the reduced
binding of drugs in diabetes, the overall hepatic clearance
may also increase leading to enhanced total drug clearance.
Diabeticdogsinthecurrentstudyalsoexhibitedlowerserum
creatinine values when compared with healthy dogs (54.8 ±
5.92μmol/L versus 65.6 ± 1.69μmol/L), which narrowly
missed signiﬁcance (P = .0885); this can be attributed, at
least partially, to hyperglycemia-induced glomerular hyper-
perfusion. Although that cyclosporine renal clearance is
negligible, increased glomerular ﬁltration rate under such
conditions is anticipated to enhance elimination of high
renally excreted drugs.
Therapeutic outcome and severity of expected toxic
side eﬀects of cyclosporine are greatly aﬀected by the area
under the plasma cyclosporine concentration-time curve
[21, 22]. Diabetic beagle dogs treated with cyclosporine
showed signiﬁcant decrease in the MRT and AUC0−∞ as
well as a great increase in the total body clearance, in
addition to dramatic reduction in the elimination half-
life of cyclosporine. Given that the volume of distribution
of cyclosporine did not change in both treated groups
regardless of the pharmacokinetic method of analysis, these
observationscanbeattributedtoanincreaseinthemetabolic
degradation of cyclosporine in the liver [34].
Very little work has been carried out to assess the eﬀect
of diabetes on cyclosporine pharmacokinetics, although
insulin and glucagon may regulate the metabolizing enzymes
and/or transporters involved in cyclosporine disposition
[14]. In streptozotocin-induced diabetic rats, D’Souza and
colleagues showed that cyclosporine clearance was reduced
by 127%, indicating that diabetes may profoundly reduce
cyclosporine metabolism [35]. Furthermore, insulin admin-
istration greatly restored cyclosporine clearance. The ﬁnd-
ings of the current work, however, demonstrated that overt
diabetes signiﬁcantly increases cyclosporine elimination in
beagle dogs. This result is consistent with the observa-
tion of lower steady-state average serum concentrations of
cyclosporine in pancreatectomized dogs relative to the nor-
mals [36]. In addition, diabetic kidney transplant recipients
exhibit a higher unbound fraction (fu), higher CL/Fss, and
lower AUC values in blood and plasma as compared to
nondiabetic patients [37]. Therefore, interspecies diﬀerences
may exist for the inﬂuence of diabetes on cyclosporineExperimental Diabetes Research 5
Table 3: Noncompartmental pharmacokinetic parameters of cyclosporine following an intravenous administration of 5mg/kg in healthy
and diabetic beagle dogs.
Parameter Estimate (Mean ± SEM)
Healthy dog Diabetic dog P value
Co (μgL −1) 3680.50 ± 661.58 3721.28 ± 638.62 .8801
MRT (hr) 25.73 ± 3.04 10.6313 ± 2.35 .0098
AUC0−t (μg∗hr L−1) 15892.66 ± 1225.49 10144.39 ± 1113.72 .0119
AUC0−∞ (μg∗hr L−1) 25181.39 ± 1513.63 12110.47 ± 1881.94 .0019
CL (L hr−1 kg−1) 0.201 ± 0.010 0.457 ± 0.076 .0019
Vss (L Kg−1)5 . 1 2 ± 0.57 4.19 ± 0.45 .2468
λz( h r −1) 0.032 ± 0.003 0.106 ± 0.037 .0125
T1/2λ (hr) 22.56 ± 2.3042 9.3194 ± 2.2896 .0125
pharmacokinetics, and further work is warranted to evaluate
the mechanism(s) of these observations. Interestingly, read-
justment of the insulin administration normalized the drug
metabolism as has been seen in experimental studies [38, 39]
which highlights the importance of proper glycemic control
to minimize the inﬂuence of diabetes on drug disposition.
5. Conclusion
The current study has demonstrated that diabetes modiﬁes
the pharmacokinetic proﬁle of cyclosporine in beagle dogs.
Increased total body clearance due to hyperglycemia and/or
associated disturbed lipid proﬁle could be the basis of this
modulation. More studies are needed to further characterize
the eﬀects and mechanisms of diabetes on the pharmacoki-
netics and pharmacodynamics of other clinically used drugs.
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